Rosanne L van den Berg, Elke Butterbrod, Casper de Boer, Lisa-Marie Schlüter, Argonde C van Harten, Charlotte E Teunissen, Elsmarieke van de Giessen, Wiesje M van der Flier, Sietske A M Sikkes
{"title":"主观认知衰退患者的流利性淀粉样蛋白相关改变。","authors":"Rosanne L van den Berg, Elke Butterbrod, Casper de Boer, Lisa-Marie Schlüter, Argonde C van Harten, Charlotte E Teunissen, Elsmarieke van de Giessen, Wiesje M van der Flier, Sietske A M Sikkes","doi":"10.1002/dad2.70063","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression.</p><p><strong>Methods: </strong>A total of 490 individuals with SCD (62 ± 8 years, 42% female, 28% amyloid-positive, 17% clinical progression) completed annual fluency assessments (mean ± SD follow-up 4.3 ± 2.9 years). Associations between fluency trajectories, amyloid status, and clinical progression were examined with linear mixed models and joint models.</p><p><strong>Results: </strong>Amyloid-positive individuals declined faster than amyloid-negative individuals on semantic fluency (<i>B</i> = -0.35, <i>p</i> < 0.001), but not on phonemic fluency (<i>B</i> = -0.06, <i>p</i> = 0.218). An annual decline of one word in semantic and phonemic fluency was associated with 22% (hazard ratio [HR] = 1.22, <i>p</i> < 0.001) and 28% (HR = 1.28, <i>p</i> = 0.004) increased risk of clinical progression.</p><p><strong>Discussion: </strong>Our results indicate that decline in semantic fluency is an early indicator of cognitive deficits in preclinical Alzheimer's disease.</p><p><strong>Highlights: </strong>Abnormal amyloid burden is associated with decline in semantic fluency.Fluency trajectories are associated with an increased risk of clinical progression.More refined measures are needed to detect the earliest language deficits.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 1","pages":"e70063"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736636/pdf/","citationCount":"0","resultStr":"{\"title\":\"Amyloid-related changes in fluency in patients with subjective cognitive decline.\",\"authors\":\"Rosanne L van den Berg, Elke Butterbrod, Casper de Boer, Lisa-Marie Schlüter, Argonde C van Harten, Charlotte E Teunissen, Elsmarieke van de Giessen, Wiesje M van der Flier, Sietske A M Sikkes\",\"doi\":\"10.1002/dad2.70063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression.</p><p><strong>Methods: </strong>A total of 490 individuals with SCD (62 ± 8 years, 42% female, 28% amyloid-positive, 17% clinical progression) completed annual fluency assessments (mean ± SD follow-up 4.3 ± 2.9 years). Associations between fluency trajectories, amyloid status, and clinical progression were examined with linear mixed models and joint models.</p><p><strong>Results: </strong>Amyloid-positive individuals declined faster than amyloid-negative individuals on semantic fluency (<i>B</i> = -0.35, <i>p</i> < 0.001), but not on phonemic fluency (<i>B</i> = -0.06, <i>p</i> = 0.218). An annual decline of one word in semantic and phonemic fluency was associated with 22% (hazard ratio [HR] = 1.22, <i>p</i> < 0.001) and 28% (HR = 1.28, <i>p</i> = 0.004) increased risk of clinical progression.</p><p><strong>Discussion: </strong>Our results indicate that decline in semantic fluency is an early indicator of cognitive deficits in preclinical Alzheimer's disease.</p><p><strong>Highlights: </strong>Abnormal amyloid burden is associated with decline in semantic fluency.Fluency trajectories are associated with an increased risk of clinical progression.More refined measures are needed to detect the earliest language deficits.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 1\",\"pages\":\"e70063\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736636/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
我们研究了主观认知衰退（SCD）患者的语义和音位流畅性与淀粉样蛋白状态和临床进展的关系。方法：共490例SCD患者（62±8岁，42%为女性，28%淀粉样蛋白阳性，17%临床进展）完成年度流利性评估（平均±SD随访4.3±2.9年）。流畅性轨迹、淀粉样蛋白状态和临床进展之间的关系通过线性混合模型和联合模型进行了检验。结果：淀粉样蛋白阳性个体语义流畅性下降速度快于淀粉样蛋白阴性个体（B = -0.35, p B = -0.06, p = 0.218）。语义和音素流利度每年下降一个单词与22%的临床进展风险增加相关（风险比[HR] = 1.22, p = 0.004）。讨论：我们的研究结果表明，语义流畅性下降是临床前阿尔茨海默病认知缺陷的早期指标。重点：异常的淀粉样蛋白负担与语义流畅性下降有关。流畅性轨迹与临床进展的风险增加有关。需要更精确的方法来发现早期的语言缺陷。
Amyloid-related changes in fluency in patients with subjective cognitive decline.
Introduction: We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression.
Methods: A total of 490 individuals with SCD (62 ± 8 years, 42% female, 28% amyloid-positive, 17% clinical progression) completed annual fluency assessments (mean ± SD follow-up 4.3 ± 2.9 years). Associations between fluency trajectories, amyloid status, and clinical progression were examined with linear mixed models and joint models.
Results: Amyloid-positive individuals declined faster than amyloid-negative individuals on semantic fluency (B = -0.35, p < 0.001), but not on phonemic fluency (B = -0.06, p = 0.218). An annual decline of one word in semantic and phonemic fluency was associated with 22% (hazard ratio [HR] = 1.22, p < 0.001) and 28% (HR = 1.28, p = 0.004) increased risk of clinical progression.
Discussion: Our results indicate that decline in semantic fluency is an early indicator of cognitive deficits in preclinical Alzheimer's disease.
Highlights: Abnormal amyloid burden is associated with decline in semantic fluency.Fluency trajectories are associated with an increased risk of clinical progression.More refined measures are needed to detect the earliest language deficits.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
